Brian Alvin Johns
Chief Scientific OfficerDr. Brian Alvin Johns Ph.D., serves as Chief Scientific Officer of Brii Biosciences Limited since January 3, 2024. He served as Chief Scientific Officer of HemoShear Therapeutics, Inc. He joined the HemoShear Therapeutics, Inc. in September 2019. Dr. Johns joins the company following a prolific career with GSK, where he co-invented Tivicay® (dolutegravir). Dr. Johns most recently served as Vice President, External Discovery Sciences for ViiV Healthcare, an HIV specialty company majority owned by GSK. In this position, he developed strategic external discovery collaborations to acquire the most relevant and cutting-edge science to employ in the HIV field. Following years of success at GSK, Dr. Johns has spent time working closely with as co-director of the UNC HIV Cure Center and Qura Therapeutics, a biotech partnership between ViiV Healthcare and UNC with the mission to find a cure for HIV. He received a PhD in Organic Chemistry from Wayne State University In 1997 and was an NIH Postdoctoral Fellow at the University of Virginia.
Positions
- Company NameBrii Biosciences LimitedStock Code02137PositionChief Scientific OfficerColleagues
- ZHZhi HongCo-founder, Executive Chairman of the Board & CEO
- ALAnkang LiCOO, Joint Secretary & Executive Director
- EDEleanor de GrootChief Technology Officer
- SQSarah QiuAssociate Director of Investor Relations
- MJMartin J. MurphyIndependent Non-executive Director
- HTHui TangIndependent Non-executive Director
- GHGregg Huber AltonIndependent Non-executive Director
